4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 94 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q1 2023. The put-call ratio across all filers is 1.35 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $50 | -15.3% | 3,904 | +20.0% | 0.00% | – |
Q2 2023 | $59 | +7.3% | 3,252 | +2.5% | 0.00% | – |
Q1 2023 | $55 | -34.5% | 3,172 | -16.2% | 0.00% | -100.0% |
Q4 2022 | $84 | -99.7% | 3,787 | +2.4% | 0.00% | – |
Q3 2022 | $30,000 | +15.4% | 3,697 | 0.0% | 0.00% | – |
Q2 2022 | $26,000 | -50.9% | 3,697 | +5.8% | 0.00% | – |
Q1 2022 | $53,000 | – | 3,495 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Octagon Capital Advisors LP | 1,566,895 | $23,691,000 | 5.12% |
Aquilo Capital Management, LLC | 1,755,506 | $26,543,000 | 3.90% |
Deep Track Capital, LP | 2,448,200 | $37,017,000 | 2.37% |
BVF INC/IL | 2,664,521 | $40,288,000 | 1.61% |
Opaleye Management Inc. | 325,000 | $4,914,000 | 1.53% |
Perigon Wealth Management, LLC | 557,475 | $8,429,000 | 0.60% |
Eagle Health Investments LP | 132,090 | $1,997,000 | 0.49% |
Casdin Capital, LLC | 555,455 | $8,398,000 | 0.38% |
VIKING GLOBAL INVESTORS LP | 3,937,914 | $59,541,000 | 0.24% |
ArrowMark Colorado Holdings LLC | 1,145,585 | $17,321,000 | 0.15% |